Buy Leqembi (lecanemab-irmb)
What is Leqembi (lecanemab-irmb) for?
Leqembi (lecanemab-irmb) is a prescription medicine used to treat patients with mild-stage cognitive impairment or dementia in Alzheimer’s disease[1].
How does Leqembi (lecanemab-irmb) work?
Leqembi (lecanemab-irmb) lessens the number of amyloid beta plaques in the brain which affects the loss of neurons. Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that selectively binds with the amyloid-beta (Aβ) aggregate forms, soluble and insoluble; as a result, the amyloid-betas (Aβ) are neutralized and eliminated[1].
Where has Leqembi (lecanemab-irmb) been approved?
Leqembi (lecanemab-irmb) was approved for patients with Alzheimer’s disease by:
- The Food and Drug Administration (FDA), USA on January, 2023[2].
References
- Full prescribing information [FDA]: Leqembi (lecanemab-irmb) (PDF)
Eisai inc., January 2023 - FDA grants accelerated approval for Alzheimer’s disease treatment
FDA, January 2023
Reviews
There are no reviews yet.